SYHX2011 for Advanced Breast Cancer
Part of Cancer clinical trials.
This study tests a new drug called SYHX2011 in people with advanced breast cancer. It looks at how well the drug works and if it is safe. The drug is a form of paclitaxel (a chemotherapy drug) bound to albumin, a protein.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced breast cancer confirmed by biopsy or cell test.
- Your tumor must be measurable on a scan (CT, MRI, etc.).
- You must be 18 years or older.
- Your overall health must be good enough for daily activities (ECOG score 0 or 1).
- You must not have severe allergies to paclitaxel or albumin, or uncontrolled brain metastases.
- You must not have serious heart, lung, nerve, or other uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
This clinical trial tests a new investigational drug (SYS6010) combined with another drug (SYH2051) or given alone, compared to standard chemotherapy, for advanced breast cancer and other solid tumors that have a specific protein called EGFR. The goal is to see if this treatment can help shrink tumors or slow their growth.
This trial tests a new drug called SYH2095 for people with advanced solid tumors, including a specific type of breast cancer (HR+/HER2-). The goal is to see if it is safe and effective. You may join if you are an adult with a tumor that can be measured and you are in generally good health.
This trial tests a new medicine called SYHA1813, alone or combined with other treatments, for people with advanced solid tumors that cannot be removed by surgery. The goal is to see if it is safe and if it can help shrink or control the tumors.
This trial tests a new drug, HX111, in people with advanced solid tumors (like sarcomas, head and neck, cervical, or breast cancer) or certain lymphomas that have not responded to standard treatments. The goal is to see if HX111 can help shrink or control the cancer.
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.